Peptide · Vial
Verified recordBPC 157
$9010mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Current batchBPC 004-012
Published result99.2% reported purity
EternaGen / Launch batch pendingPeptide · Research use only
Semax
$95CAD
An ACTH-fragment-derived heptapeptide explored in intranasal neurobiology and neurotrophic-signalling research.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
Semax, clearly explained.
An ACTH-fragment-derived heptapeptide explored in intranasal neurobiology and neurotrophic-signalling research.
Overview
Semax has been examined in small human neuroimaging and clinical studies, while much of the mechanistic literature comes from animal models. Those findings do not establish the safety, efficacy or performance of a separately sourced research material.
Semax is a seven-amino-acid synthetic peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is derived from an adrenocorticotropic-hormone fragment and has been studied through intranasal administration in a small number of human and animal experiments.- Format
- Nasal spray
- Available strengths
- 10mg
- Batch
- Launch batch pending
- Purity
- Verification pending
Research at a glanceLimited small human studies plus preclinical mechanistic evidence
Reviewed 31 July 2026View research context Specifications
Product details
- Sequence / identity
- MEHFPGP
- Molecular formula
- C37H51N9O10S
- Molecular weight
- 813.9 g/mol
- Storage and handling
- Launch handling specifications will be published with the verified batch record. Protect the sealed research material from direct light in the interim.
Batch documentationLaunch record pending
The batch code, analytical results and handling specifications will publish after verification.
- Batch
- Launch batch pending
- Purity
- Verification pending
Important research-use boundary
This catalogue entry describes a research material, not an approved therapeutic formulation. Published findings do not provide directions for personal use and cannot verify the safety or performance of a separately sourced material.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Resting-state brain networks
A small placebo comparison in healthy volunteers measured default-mode-network topology shortly after intranasal exposure.
Evidence so far: Small exploratory human studyQuestion 02
Neurotrophic signalling
Rat studies have examined specific binding and short-term changes in brain-derived neurotrophic factor after intranasal administration.
Evidence so far: Preclinical mechanistic evidenceQuestion 03
Translation and safety
The available literature does not establish long-term safety, broadly applicable benefit or equivalence between research materials and studied formulations.
Evidence so far: Major evidence gapProposed mechanism
How researchers are investigating the mechanism.
Animal research has examined Semax binding and changes in brain-derived neurotrophic factor in specific brain regions. A small human fMRI experiment measured short-term changes in resting-state network topology. These observations are exploratory and do not establish a clinical outcome.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Small resting-state fMRI study in 24 healthy volunteers assigned to Semax or placebo
- What researchers saw
- Investigators reported a difference in the rostral default-mode-network subcomponent after intranasal exposure.
- Why that is not the whole story
- A short neuroimaging signal in a small exploratory sample is not evidence of durable cognitive or clinical benefit.
Study 02Intranasal binding and BDNF experiments in rat basal forebrain
- What researchers saw
- The study reported specific binding and a short-term increase in BDNF protein in one brain region.
- Why that is not the whole story
- A rat mechanistic observation cannot determine human efficacy, safety or an appropriate administration protocol.
Evidence gaps
What remains unknown?
- Larger independently replicated human trials with prespecified clinical outcomes are lacking.
- Long-term safety, formulation comparability and route-specific tolerability remain insufficiently characterized.
- A published experiment cannot authenticate the identity or performance of a separate catalogue material.
Primary sources
Check the original sources.
- Primary exploratory human studyPanikratova et al. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med. 2018. PMID 30225715.
- Primary preclinical studyDolotov et al. Semax binding and BDNF protein in rat basal forebrain. J Neurochem. 2006. PMID 16635254.
- Compound identity recordPubChem CID 9811102. Semax molecular identity and sequence record.
Related products
Continue comparing.
Peptide · Vial
Verified recordGHK-CU
From CA$5550mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Current batchGHK 006-031
Published result99.5% reported purity
Peptide · Pen
Verified recordMOTS-c
From CA$20010mg40mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Current batchMOTS 005-021
Published result99.0% reported purity